Brought to you by 
Boehringer Ingelheim Gains Worldwide Rights to Bridge's IPF Candidate BBT-877; Deal Terminated
10 Nov 2020
Executive Summary
Boehringer Ingelheim GmbH licensed exclusive worldwide rights to Bridge Biotherapeutics Inc.'s BBT877 for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boehringer Ingelheim Gains Worldwide Rights to Bridge's IPF Candidate BBT-877; Deal Terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice